Abstract
An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have